Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
Debra Bowes, MBEE has 30 years of biotech/pharma experience. She serves as a fractional executive to two drug development biotechs. She is a cell therapy advisor for Harrington Discovery Institute, as well as Case Western Reserve University.
Previously, Dr. Bowes was Chief Business Officer, CARMA Cell Therapies for MaxCyte, where she built the drug development team, filed the company’s first cell therapy IND and initiated their first clinical trial. In addition, she negotiated and closed three cell therapy platform licenses with notable cell therapy companies.
In 2006, Dr. Bowes founded Chevy Chase BioPartners, a consulting firm specializing in Commercial Strategic Planning and Licensing for biotech/pharmaceutical companies. During this time, she held contract positions as interim CEO for CapGenesis Therapeutics and VP of Licensing and Commercial Strategy for CBLI Pharma. Prior to starting CCBP, Dr. Bowes was the Senior Director of New Product Planning for MedImmune. Here, she built a department responsible for supporting the strategic business planning aspects of MedImmune’s R&D pipeline. Prior to MedImmune, she held the position of Senior Director, Corporate Development for Amylin Pharmaceuticals.
Previously, she spent several years at Pfizer Pharmaceuticals in Licensing and New Product Planning focusing on oncology. Serving as Worldwide Market Manager for Centocor, she was responsible for managing and expanding oncology licensing agreements with European and Asian partners. She started her pharmaceutical career with Hybritech, Inc., where she held positions of growing responsibility in sales, marketing, market research and licensing. She is a former National President, current National Board Member and member of National Director Emeritus for Women in BIO. She has been an industry speaker since 2005, and she currently serves on Industry Corporate Boards.
Dr. Bowes holds a Master’s (MBEE) from Johns Hopkins University, a Bachelor of Science degree in cell biology from the University of Cincinnati, and a Medical Technologist (MT) certification from the American Society of Clinical Pathologists.